ClinicalTrials.gg
RecruitingNCT07113522ASCEND-IBDUpdated Mar 12, 2026

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

A Phase 2 interventional study of MT-501 and MT-201 in Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn's Disease, sponsored by Mirador Therapeutics, Inc.. Recruiting at 66 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Mirador Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Planned enrollment
74th of 327
140 · median 50
Started
2025
with 29 others
Phase 2
63 of 463
13 open now
Primary completion
2027-04
later than 44 of 121 live
Registered
428th of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 74th largest by planned enrollment of the 327 interventional ones that give a count, is one of 30 that started in 2025, is one of 63 in phase 2, reaches primary completion later than 44 of the 121 other live ones, and was the 428th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

Read the detailed description

The purpose of this platform study is to assess the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) to evaluate multiple oral or parenteral experimental therapies for moderately to severely active Crohn's Disease or Ulcerative Colitis.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis (UC)
  • Crohn's Disease

Keywords

  • Inflammatory Bowel Diseases
  • ASCEND-IBD
  • Ulcerative Colitis
  • UC
  • CD
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria-Crohn's Disease:

  • Diagnosis of Crohn's Disease (CD), as confirmed by endoscopy and histopathology
  • Moderately to severely active CD as defined by Clinical Disease Activity Index (CDAI) and Simple Endoscopic Score (SES-CD)
  • Meets drug stabilization requirements

Inclusion Criteria-Ulcerative Colitis:

  • Diagnosis of Ulcerative Colitis (UC), as confirmed by endoscopy and histopathology
  • Moderately to severely active UC as defined by a 3-component MMCS
  • Meets drug stabilization requirements

Exclusion Criteria-Crohn's Disease:

  • Diagnosis of indeterminate colitis
  • Suspected or diagnosed intra-abdominal or perianal abscess at Screening
  • Previous small bowel resection with combined resected length of > 100 cm or previous colonic resection of > 2 segments
  • CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement

Exclusion Criteria-Ulcerative Colitis:

  • Current evidence or within recent history (within last 6 months) of fulminant colitis, toxic megacolon, or bowel perforation
  • Current stoma or impending need for colostomy or ileostomy
  • Received IV within 14 days prior to Screening or during the Screening Phase
  • Previous total proctocolectomy or subtotal colectomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Intervention Specific Appendix- Crohn's Disease

    Participants will receive MT-501 Tablets

    Drug: MT-501

  • Experimental
    Intervention Specific Appendix- Ulcerative Colitis

    Participants will receive MT-501Tablets

    Drug: MT-501

  • Experimental
    Intervention Specific Appendix- Crohn's Disease with Standard of Care

    Participants will receive multiple intravenous doses of MT-201 with standard of care

    Drug: MT-201

Interventions

  • DrugMT-501

    MT-501

  • DrugMT-201

    MT-201

06

What researchers measure

Primary outcomes

  1. Assess the proportion of participants reporting treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) leading to discontinuation, and markedly abnormal laboratory values

    Time frame: Up to 13 weeks

  2. Assess the Proportion of Participants with Endoscopic Response (CD)

    Endoscopic response as assessed by SES-CD score.

    Time frame: 13 weeks

  3. Assess the Proportion of Participants Endoscopic Improvement (UC)

    Endoscopic improvement as assessed by MES.

    Time frame: 12 weeks

  4. Assess the Proportion of Participants with Clinical Remission (CD)

    Clinical remission as assessed by CDAI score.

    Time frame: 13 weeks

  5. Assess the Proportion of Participants with Clinical Remission (UC)

    Clinical remission as assessed by endoscopy, rectal bleeding and stool frequency.

    Time frame: 12 weeks

Secondary outcomes

  1. Assess the Proportion of Participants with Clinical Remission (CD)

    CD: Clinical remission as assessed by CDAI score.

    Time frame: 13 weeks

  2. Assess the Proportion of Participants with Clinical Remission (UC)

    Clinical remission as assessed by endoscopy, rectal bleeding, and stool frequency.

    Time frame: 12 weeks

  3. Assess the Proportion of Participants with Symptomatic Remission (CD and UC)

    Symptomatic remission as assessed by patient reported outcomes.

    Time frame: Up to 13 weeks

  4. Assess the Proportion of Participants with Clinical Response (CD)

    CD: Clinical response as assessed by CDAI score.

    Time frame: 13 weeks

  5. Assess the Proportion of Participants with Clinical Response (UC)

    UC: Clinical response as assessed by MMCS.

    Time frame: 12 weeks

  6. Assess the Proportion of Participants with Endoscopic and Clinical Response (CD Only)

    Endoscopy as assessed by SES-CD and clinical response as assessed by CDAI score.

    Time frame: 13 weeks

  7. Assess the Proportion of Participants with Histologic Response (UC Only)

    Histologic response as assessed by the RHI.

    Time frame: 12 weeks

  8. Assess the Proportion of Participants with Histologic Remission (UC only)

    Histologic remission as assessed by the RHI.

    Time frame: 12 weeks

  9. Assess the Proportion of Participants with Histologic-Endoscopic Mucosal Improvement (UC only)

    Histologic-endoscopic mucosal improvement as assessed by the Geboes score and MES.

    Time frame: 12 weeks

  10. Characterize the Change in Endoscopy Score (CD)

    CD: Endoscopy score as assessed by SES-CD.

    Time frame: 13 weeks

  11. Characterize the Change in Endoscopy Score (UC)

    Endoscopy score as assessed by MES.

    Time frame: 12 weeks

  12. Characterize the Change in Histology Score (CD)

    Histology as assessed by GHAS and RHI.

    Time frame: 13 weeks

  13. Characterize the Change in Histology Score (UC)

    Histology as assessed by Geobes, RHI and NHI

    Time frame: 12 weeks

  14. Asses the Pharmacokinetics (PK) (e.g., Trough Concentration [Ctrough]) of Investigational Drug

    Time frame: Up to 13 weeks

  15. Assess immunogenicity

    Time frame: 13 weeks

07

Study locations

66 of 66 sites recruiting
  • Mirador Therapeutics Selected Site
    Birmingham, Alabama 35235, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Scottsdale, Arizona 85258, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Sun City, Arizona 85351, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Colorado Springs, Colorado 80921, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Littleton, Colorado 80120, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Miami, Florida 33134, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Miami, Florida 33165, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Miami, Florida 33176, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Orlando, Florida 32825, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Palmetto Bay, Florida 33176, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Pensacola, Florida 32504, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Atlanta, Georgia 30342, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Snellville, Georgia 30078, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Glenview, Illinois 60026, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Gurnee, Illinois 60031, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Lafayette, Louisiana 70503, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Marrero, Louisiana 70072, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Shreveport, Louisiana 71105, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Ypsilanti, Michigan 48197, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Bridgeton, Missouri 63044, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Kansas City, Missouri 64114, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Liberty, Missouri 64068, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Las Vegas, Nevada 89128, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    New York, New York 10016, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Rochester, New York 14618, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    High Point, North Carolina 27262, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Raleigh, North Carolina 27612, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Cincinnati, Ohio 45219, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Liberty Township, Ohio 45044, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Providence, Rhode Island 02904, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Greenville, South Carolina 29607, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Cordova, Tennessee 38018, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Dallas, Texas 75230, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Garland, Texas 75044, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Georgetown, Texas 78628, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Houston, Texas 77090, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Lubbock, Texas 79424, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Southlake, Texas 76092, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Tyler, Texas 75701, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Webster, Texas 77598, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Bellevue, Washington 98004, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Silverdale, Washington 98383, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Tacoma, Washington 98405, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Milwaukee, Wisconsin 53215, United States
    Recruiting
  • Mirador Therapeutics Selected Site
    Toronto, Canada
    Recruiting
  • Mirador Therapeutics Selected Site
    Kutaisi, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Marneuli, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Tbilisi, 0102, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Tbilisi, 0144, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Tbilisi, 0159, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Tbilisi, 0178, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Tbilisi, 0180, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Tbilisi, 4600, Georgia
    Recruiting
  • Mirador Therapeutics Selected Site
    Chisinau, Moldova
    Recruiting
  • Mirador Therapeutics Selected Site
    Chisinau, Moldova
    Recruiting
  • Mirador Therapeutics Selected Site
    Ivano-Frankivsk, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Kyiv, 02002, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Kyiv, 02091, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Kyiv, 03037, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Kyiv, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Lutsk, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Lviv, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Poltava, Ukraine
    Recruiting
  • Mirador Therapeutics Selected Site
    Vinnytsia, Ukraine
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.

Of 61 phase 2 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 43. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Aug 8, 2025
StartActual
Jun 26, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Feb 4, 2028
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07113522
Lead sponsor
Mirador Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Jun 26, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Feb 4, 2028 (estimated)
Last update
Mar 12, 2026

Study contacts

ASCEND-IBD Trial Center
Contact
clinicaltrials@miradortx.com
844-206-4980

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adecatumumab

Start the discussion